Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)

Area of Science:

• Pharmacology
• Drug Discovery
• Fibrosis Research

Background:

• Fibrosis is a significant cause of organ damage and mortality.
• The lysophosphatidic acid receptor type 1 (LPA1) signaling pathway, including LPA1 and its downstream target Rho-associated coiled-coil forming protein kinase (ROCK), is implicated in fibrosis pathogenesis.
• Developing effective anti-fibrosis drugs is challenging due to the complex mechanisms underlying the disease.

Approach:

• This review analyzes patents for LPA1 antagonists (since 2010) and ROCK inhibitors (since 2017) using the Cortellis Drug Discovery Intelligence database.
• The patent analysis categorizes compounds by their chemical scaffolds.
• Data on LPA1 antagonists that have advanced into clinical trials is incorporated.

Key Points:

• Numerous LPA1 antagonist patents have been filed for fibrosis treatment over the last decade.
• A small number of these compounds have progressed to clinical trials.
• Diverse chemical scaffolds are being explored by different entities for developing fibrosis therapies targeting LPA1 and ROCK.

Conclusions:

• The LPA1 signaling pathway presents a viable target for anti-fibrosis drug development.
• LPA1 and ROCK serve as competitive targets for novel therapeutic strategies against fibrosis.
• Continued research into LPA1 antagonists and ROCK inhibitors may yield future treatment options for patients suffering from fibrosis.